

CAMZYOS® REMS

Pharmacy Authorized Representative Knowledge Assessment

Instructions:

- 1. Complete and submit this *Pharmacy Authorized Representative Knowledge Assessment* to the REMS:
 - ▶ Online at CAMZYOSREMS.com, or
 - ▶ Print and fax the form to the CAMZYOS REMS at 833-299-9539
- 2. To complete certification, enroll in the REMS by completing and submitting the *Pharmacy Enrollment Form*

Complete all required fields on this form to avoid a delay in the enrollment process. Upon completion of these steps, the REMS will notify you of your successful certification within 1 business day.

| Pharmacy Authorized Representative Information (Fields marked * are REQUIRED) | | | | | |
|---|--------------------|-------|----------------------|--|--|
| *First Name: | Middle Initial: | | *Last Name: | | |
| *Title: | | | | | |
| *Pharmacy NPI #: | | | | | |
| *Pharmacy Name: | | | | | |
| *Phone: | | *Fax: | | | |
| Area Code/Telephone Number | | | Area Code/Fax Number | | |
| *Email: | | | | | |



For internal use only

Phone: 833-628-7367 Fax: 833-299-9539 CAMZYOSREMS.com

CAMZYOS® REMS

Pharmacy Authorized Representative Knowledge Assessment

For Questions 1–10, select the correct answer. All questions must be answered correctly. Question 1

| Question 1 | |
|--|--|
| The risk being mitigated in the CAMZYOS REMS is: | |

| 0 | A. Liver function test elevat | ions (>3 times | upper limit | of normal) |
|---|-------------------------------|----------------|-------------|------------|

O B. Neutropenia

O C. Heart failure due to systolic dysfunction

O **D.** Severe skin reactions

Question 2

Which of the following are objectives of the CAMZYOS REMS?

| 0 | Α. | Monitor fo | or detection | of heart fa | ailure due | to systolic d | vsfunction w | vith periodic | echocardiograms |
|---|----|------------|--------------|-------------|------------|---------------|--------------|---------------|-----------------|
| | | | | | | | | | |

O B. Reduce liver toxicity caused by CAMZYOS

O C. Screen for drug interactions prior to each dispense

O D. Options A and B only

O E. Options A and C only

Question 3

What is the recommended starting dose of CAMZYOS?

O A. 2.5 mg once daily

O **B.** 5 mg once daily

O **C.**10 mg every other day

Question 4

With every prescription of CAMZYOS dispensed, the pharmacy needs to:

O A. Obtain authorization to dispense CAMZYOS

O B. Document the prescribed dose on the CAMZYOS REMS website or by calling the REMS Call Center

O C. Complete and submit the *Drug Interaction and Counseling Checklist for Pharmacies* to the REMS

O. Provide the **Patient Brochure** with each shipment of CAMZYOS

O E. All of the above

Question 5

If the authorized representative of the pharmacy changes, the new representative needs to enroll in the CAMZYOS REMS.

O A. TRUE O B. FALSE

Question 6

Patients can elect not to enroll in the REMS and still receive treatment with CAMZYOS.

O A.TRUE O B.FALSE

For internal use only

Phone: 833-628-7367 Fax: 833-299-9539 CAMZYOSREMS.com

CAMZYOS® REMS

Pharmacy Authorized Representative Knowledge Assessment

Question 7

All of the following must be completed as part of the *Drug Interaction and Counseling Checklist for Pharmacies*:

- O A. Review and document prescription and nonprescription medications and supplements with the patient
- O B. Instruct the patient to contact their healthcare provider if new or worsening symptoms of heart failure occur
- O **C.** Counsel the patient to notify their healthcare provider and pharmacist prior to starting any new prescription or nonprescription medications or supplements
- O D. Options A and B
- O E. All of the above

Question 8

A certified pharmacy may dispense up to how many days' supply of CAMZYOS?

- O A.14
- O B.35
- O **C**.95
- O **D.** 120

Question 9

The pharmacist needs to verify which of the following to obtain authorization for the first dispense of CAMZYOS:

- O A. The prescriber is certified in the CAMZYOS REMS
- O B. The patient is enrolled in the CAMZYOS REMS
- O C. The *Drug Interaction and Counseling Checklist for Pharmacies* has been completed and submitted to the CAMZYOS REMS
- O **D.** The patient has completed a liver function test
- O E. Options A, B, and C

Question 10

Which of the following are contraindications for CAMZYOS?

- O A. Concomitant use of moderate to strong CYP2C19 inhibitors
- O B. Concomitant use of moderate to strong CYP2C19 inducers
- O C.Concomitant use of strong CYP3A4 inhibitors
- O **D.** Concomitant use of moderate to strong CYP3A4 inducers
- O E. Options A and C only
- O F. All of the above



For internal use only



Phone: 833-628-7367 Fax: 833-299-9539 CAMZYOSREMS.com